Mirati Therapeutics, Inc. (MRTX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
139.01-11.76 (-7.80%)
As of 1:28PM EDT. Market open.
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 150.77 |
| Open | 150.05 |
| Bid | 136.60 x 800 |
| Ask | 136.89 x 800 |
| Day's Range | 133.50 - 150.05 |
| 52 Week Range | 91.90 - 249.42 |
| Volume | 994,157 |
| Avg. Volume | 466,040 |
| Market Cap | 7.136B |
| Beta (5Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.96 |
| Earnings Date | Aug 04, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 240.00 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
- Analyst Report: Gilead Sciences, Inc.
- Insider Monkey
Were Hedge Funds Right About Piling Into Mirati Therapeutics (MRTX)?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings […]
- Zacks
Moving Average Crossover Alert: Mirati Therapeutics (MRTX)
Mirati Therapeutics (MRTX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- Motley Fool
This Is How Amgen Avoided a Catastrophic Q1 Update
Despite disappointing results that missed expectations, progress with an important new cancer drug saved the day.
© 2021 Verizon Media. All rights reserved.
